Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 9/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2848674 | 1.00 | CNR2 (0.41) | CNR2LMNACNR1KDM4EMEN1 | |
| SCHEMBL5327482 | 1.00 | CNR2 (0.41) | CNR2LMNACNR1KDM4EMEN1 | |
| SCHEMBL13411526 | 0.87 | CNR2 (0.57) | CNR2CNR1CYP2C9GPR55 | |
| SCHEMBL5468102 | 0.86 | CNR2 (0.58) | CNR2CNR1CYP2C9TDP1GPR55 | |
| SCHEMBL5330939 | 0.86 | CNR2 (0.58) | CNR2CNR1CYP2C9TDP1GPR55 | |
| SCHEMBL5330941 | 0.86 | CNR2 (0.58) | CNR2CNR1CYP2C9TDP1GPR55 | |
| SCHEMBL5479831 | 0.86 | CNR2 (0.58) | CNR2CNR1CYP2C9TDP1GPR55 | |
| SCHEMBL5468104 | 0.86 | CNR2 (0.58) | CNR2CNR1CYP2C9TDP1GPR55 | |
| SCHEMBL3888012 | 0.85 | CNR2 (0.38) | CNR2LMNACNR1 | |
| SCHEMBL13411524 | 0.84 | CNR1 (0.60) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155723-A1 | Tetrahydro-pyranopyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-05 | — | — | US | claimed |
| WO-2007001939-A1 | TETRAHYDRO-PYRANOPYRAZOLE COMPOUNDS DISPLAYING CANNABINOID MODULATING ACTIVITIES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-04 | — | — | WO | claimed |
| WO-2007001939-A1 | TETRAHYDRO-PYRANOPYRAZOLE COMPOUNDS DISPLAYING CANNABINOID MODULATING ACTIVITIES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155723-A1 | Tetrahydro-pyranopyrazole cannabinoid modulators | CNR2, CNR1, GPR18 | CNR2 1/4885LMNA 4526/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.